State Street’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,447,416
| Closed | -$98.2M | – | 3868 |
|
|
2019
Q3 | $98.2M | Sell |
1,447,416
-258,782
| -15% | -$17.8M | 0.01% | 1009 |
|
|
2019
Q2 | $99.3M | Buy |
1,706,198
+479,679
| +39% | +$28.4M | 0.01% | 1044 |
|
|
2019
Q1 | $85.9M | Buy |
1,226,519
+193,294
| +19% | +$14.3M | 0.01% | 1103 |
|
|
2018
Q4 | $66.5M | Sell |
1,033,225
-50,505
| -5% | -$3.54M | 0.01% | 1171 |
|
|
2018
Q3 | $76.1M | Buy |
1,083,730
+427,925
| +65% | +$25M | 0.01% | 1267 |
|
|
2018
Q2 | $33.1M | Sell |
655,805
-182,002
| -22% | -$7.22M | ﹤0.01% | 1778 |
|
|
2018
Q1 | $26.2M | Buy |
837,807
+199,162
| +31% | +$6.61M | ﹤0.01% | 1863 |
|
|
2017
Q4 | $21.8M | Buy |
638,645
+101,117
| +19% | +$3.22M | ﹤0.01% | 1992 |
|
|
2017
Q3 | $17.3M | Buy |
537,528
+20,215
| +4% | +$638K | ﹤0.01% | 2127 |
|
|
2017
Q2 | $16.8M | Buy |
517,313
+12,696
| +3% | +$402K | ﹤0.01% | 2115 |
|
|
2017
Q1 | $15.9M | Sell |
504,617
-40,502
| -7% | -$1.2M | ﹤0.01% | 2107 |
|
|
2016
Q4 | $16M | Buy |
545,119
+33,975
| +7% | +$1.04M | ﹤0.01% | 2049 |
|
|
2016
Q3 | $14.8M | Buy |
511,144
+46,634
| +10% | +$1.3M | ﹤0.01% | 1968 |
|
|
2016
Q2 | $12M | Sell |
464,510
-37,929
| -8% | -$1.01M | ﹤0.01% | 2121 |
|
|
2016
Q1 | $12.4M | Buy |
502,439
+24,331
| +5% | +$668K | ﹤0.01% | 2042 |
|
|
2015
Q4 | $16.8M | Sell |
478,108
-764,781
| -62% | -$20.5M | ﹤0.01% | 1840 |
|
|
2015
Q3 | $26.3M | Sell |
1,242,889
-814
| -0.1% | -$21K | ﹤0.01% | 1566 |
|
|
2015
Q2 | $34.6M | Buy |
1,243,703
+407,571
| +49% | +$11.5M | ﹤0.01% | 1485 |
|
|
2015
Q1 | $25.5M | Buy |
836,132
+160,934
| +24% | +$5.12M | ﹤0.01% | 1678 |
|
|
2014
Q4 | $21.6M | Buy |
675,198
+61,309
| +10% | +$2M | ﹤0.01% | 1747 |
|
|
2014
Q3 | $17.4M | Sell |
613,889
-54,196
| -8% | -$1.51M | ﹤0.01% | 1851 |
|
|
2014
Q2 | $18.3M | Sell |
668,085
-214,896
| -24% | -$5.72M | ﹤0.01% | 1865 |
|
|
2014
Q1 | $23.3M | Buy |
882,981
+290,673
| +49% | +$8.34M | ﹤0.01% | 1667 |
|
|
2013
Q4 | $17.3M | Sell |
592,308
-31,997
| -5% | -$1.02M | ﹤0.01% | 1852 |
|
|
2013
Q3 | $19.1M | Sell |
624,305
-1,461
| -0.2% | -$48.9K | ﹤0.01% | 1729 |
|
|
2013
Q2 | $19.8M | Buy |
+625,766
| New | +$20.6M | ﹤0.01% | 1636 |
|
State Street's GHDX Position: Q4 2019 in Review
State Street sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 1,447,416 shares — an estimated $98.2M sold.
State Street first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $99.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- State Street reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- State Street sold 1,447,416 Genomic Health, Inc. shares in Q4 2019, an estimated $98.2M.
- State Street first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- State Street's Genomic Health, Inc. position peaked at $99.3M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on State Street's 13F filing for Q4 2019, filed 6 Feb 2020.